Blood pressure-lowering effects of different dosage forms of orally administered valsartan on spontaneously hypertensive rats

• Main Authors: Hsu, SHIH-EN, 徐士恩
• Other Authors: LIN, CHIAN-YUH
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/y29sh8

碩士 === 嘉南藥理大學 === 藥學系 === 105 === Hypertension is a risk factor for cardiovascular disease in Taiwan, the first line of its clinical treatment, valsartan, which is an angiotensin II receptor blocker and not easily soluble in water. Previous studies have found several methods to improve valsartan’s low solubility, and were further improved that it could increase the valsartan concentration in blood of animal's studies. However, there is no any experiment to demonstrate the blood pressure-lowering effect on hypertensive animals. Therefore, the purpose of this study has two aspects. First, to find a formula that can dissolve more valsartan in solvents and increase the higher bioavailability. Second, to produce different dosage forms in the same formula to apply in hypertensive rats, and observe whether there are different blood pressure-lowering effects. The method is mixing several kinds of solvents which can dissolve valsartan to form the composite solvent. The composite solvent is a specific formula that has the maximum solubility of valsartan. We then make the different dosage forms of the specific formula. Each of the different dosage forms was fed hypertensive rats. The blood pressure of the hypertensive rat was measured by the non-invasive measuring machine. The results show that the composite solvent greatly increase the solubility of valsartan more than 2,000 times of previous studies. The different dosage forms of the composite solvent have different effects of lowering blood pressure on the hypertensive rats. The dosage form of the new artificial oil body works best. In conclusion, this study has found a higher solubility formula for valsartan, and a new dosage form of the artificial oil body achieving a better blood pressure-lowering effect. It may provide one of the treatment to solve the low solubility and bioavailability of orally administered valsartan for the hypertensive patients.